Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 12/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.33 |
| ▸ | SMC2 | O95347 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.33 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862127 | 0.90 | MEN1 (0.55) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL1042057 | 0.90 | MAP2K1 (0.41) | MEN1KMT2ATDP1MAP2K1MAPT | |
| SCHEMBL2885084 | 0.89 | MAP2K1 (0.44) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL3860786 | 0.88 | MEN1 (0.41) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL3864888 | 0.86 | MEN1 (0.40) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL5988795 | 0.77 | MEN1 (0.55) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL6016689 | 0.77 | MAP2K1 (0.40) | MEN1KMT2ATDP1MAP2K1MAPT | |
| SCHEMBL3861306 | 0.77 | MAP2K1 (0.40) | MEN1KMT2ATDP1MAP2K1MAPT | |
| SCHEMBL1039779 | 0.76 | MAP2K1 (0.40) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL4826778 | 0.76 | MAP2K1 (0.39) | MEN1KMT2ATDP1MAP2K1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842816-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2010-11-30 | — | — | US | claimed |
| EP-1663210-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2009-04-22 | — | — | EP | claimed |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2007-12-27 | — | — | US | claimed |
| US-7235537-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. (US) | 2007-06-26 | — | — | US | claimed |
| JP-2007504139-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1663210-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| EP-1482932-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-05 | — | — | EP | claimed |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED (IE) | 2005-06-30 | — | — | US | claimed |
| WO-2005023251-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | claimed |
| EP-1482932-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | claimed |
| US-20040116710-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | claimed |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | claimed |
| WO-2003077914-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | claimed |
| US-20240390488-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | GENENTECH, INC. (US) | 2024-11-28 | — | — | US | disclosed |
| US-20220105180-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| US-10946093-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | GENENTECH, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED (IE) | 2005-06-30 | — | — | US | disclosed |
| WO-2005023251-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20040116710-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946093-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | CD274, PDCD1, PDCD1LG2 | MEN1 2626/4885KMT2A 1223/4885TDP1 2455/4885 |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CDK2 | MEN1 1587/4885KMT2A 1258/4885TDP1 1139/4885 |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | BRAF, CCNI, NRAS | MEN1 1151/4885KMT2A 1415/4885TDP1 1269/4885 |
| US-20240390488-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | CD274, PDCD1, PDCD1LG2 | MEN1 2626/4885KMT2A 1223/4885TDP1 2455/4885 |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | MEN1 1893/4885KMT2A 1407/4885TDP1 1308/4885 |
| US-20220105180-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | CD274, PDCD1, PDCD1LG2 | MEN1 2626/4885KMT2A 1223/4885TDP1 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.